Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Show other versions (1)

Bibliographic Details
Main Authors:	Sami N. Nasrallah, L. Raymond Reynolds
Format:	Article
Language:	English
Published:	SAGE Publishing 2012-04-01
Series:	Clinical Medicine Insights: Endocrinology and Diabetes
Online Access:	http://la-press.com/insulin-degludec-the-new-generation-basal-insulin-or-just-another-basa-a3132

Similar Items

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-01-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Insulin degludec: overview of a novel ultra long-acting basal insulin.
by: Gough, S, et al.
Published: (2013)

Insulin degludec: Overview of a novel ultra long-acting basal insulin
by: Gough, S, et al.
Published: (2013)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang F, et al.
Published: (2012-07-01)

Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients
by: Sukhminder Jit Singh Bajwa, et al.
Published: (2015-01-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

Concentrated insulins: the new basal insulins
by: Lamos EM, et al.
Published: (2016-03-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
by: Han Na Jang, et al.
Published: (2019-12-01)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Pediatric diabetes: Potential for insulin degludec
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
by: Hongzhong Liu, et al.
Published: (2022-04-01)

Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
by: Han Na Jang, et al.
Published: (2022-01-01)

Future of newer basal insulin
by: S V Madhu, et al.
Published: (2013-01-01)

Cardiovascular effects of basal insulins
by: Mannucci E, et al.
Published: (2015-07-01)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
by: Junko Oya, et al.
Published: (2021-11-01)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
by: Aye MM, et al.
Published: (2014-04-01)

Lixisenatide as add-on therapy to basal insulin
by: Brown DX, et al.
Published: (2013-12-01)

Efficacy and safety of ultra-long-acting insulin degludec
by: Ammar Wakil, et al.
Published: (2012-04-01)

Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
by: Rodrigo Oliveira Moreira, et al.
Published: (2018-04-01)

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.)
by: Sang Youl Rhee
Published: (2020-03-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022-10-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Mizuho Yamabe
Published: (2019-11-01)

Basal insulin therapy in type 2 diabetes.
by: Bethel, M, et al.
Published: (2005)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Inpatient hyperglycemia management: the opportunities of a new basal insulin
by: Natalino Simioni
Published: (2016-06-01)

Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India
by: Rajiv Kovil
Published: (2022-01-01)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017-04-01)

The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling
by: Catarina Cammalleri, et al.
Published: (2003-01-01)

Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)

The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021-02-01)

Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy
by: Pešić Milica, et al.
Published: (2007-01-01)